B-
BiotechTV - News
Jefferies London 2026: Generate Biomedicines' CEO Mike Nally describes the rationale behind a recent CAR-T deal with Anthropic, updates us on the company's TSLP, and more
0:00-10:03
He describes the win-win nature of working with Anthropic, which is related to redesigning CAR T-Cell Signaling. Plus, he discusses room for improvement in the TSLP space and why he believes Generate's candidate could be best in class.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/Jefferies-London-2026-Generate-Biomedicines-CEO-Mike-Nally-describes-the-rationale-behind-a-recent-CAR-T-deal-with-Anthropic--updates-us-on-the-companys-TSLP--and-more-e3sghk4
Published
November 16, 2026
Duration
10 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#jefferieslondon #generatebiomedicinesceo #companystslp #lifesciences
